In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ViroPharma's Second Act: First a Tough One to Follow

Executive Summary

In the year since biotech ViroPharma acquired Vancocin, it's transformed itself from a development-style biotech into an earnings-driven success. One result: a new shareholder base that likes regular profit increases and may not tolerate the lower margins that come with additional R&D spending or in-licensing costs. But with generics and other competitors on the near-term horizon, ViroPharma needs a dramatic second-act solution.

You may also be interested in...



Shire’s ViroPharma Purchase Aims To Build Rare Disease Giant

Shire is buying ViroPharma at a steep premium to acquire its pipeline assets, notably C1 esterase inhibitor Cinryze, which the London-listed specialty pharma plans to expand internationally, initially to treat hereditary angioedema and later for other rare diseases.

Aton Pharma Moves Beyond Its Merck Connections With Pick-up From Bristol

Specialty pharma focuses on acquiring marketing rights to mature products underappreciated in their market areas.

Two Steps Back: Ligand Ditches Commercial Assets

In early September, Ligand Pharmaceuticals announced it had unloaded its entire portfolio of marketed compounds, bringing in $518 million. The move goes against the grain of conventional wisdom in the biopharma world these days, where companies are still scrambling for clinical and commercial assets to forward integrate their businesses.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

ID1125347

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel